Elan Corp. PLC plans to pay about $338 million for a privately held, Austrian drug developer and at least $110 million for stakes in two other companies as the Irish drugmaker continues to refocus after unloading its main revenue source, an ownership stake in the multiple sclerosis drug Tysabri.
The Dublin-based company said Monday it will buy AOP Orphan Pharmaceuticals in a cash-and-stock deal valued at about 263.5 million euros. AOP, based in Vienna, focuses on rare diseases in hematology/oncology and cardiology/pulmonology. Elan also may make up milestone payments of up to 270 million euros ($346.7 million) depending on the development of potential treatments in late-stage clinical research.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.